CAM
FTH

Cresset Asset Management’s Faeth Therapeutics FTH Stock Holding History

Cresset Asset Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-984
Closed -$7.75K – 1743
2025
Q1 		$7.75K Hold
984
– – ﹤0.01% 1704
2024
Q4 		$9.64K Hold
984
– – ﹤0.01% 1737
2024
Q3 		$11.8K Hold
984
– – ﹤0.01% 2164
2024
Q2 		$12.2K Hold
984
– – ﹤0.01% 2079
2024
Q1 		$20.7K Buy
+984
New +$17K ﹤0.01% 1880

Other funds holding FTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Cresset Asset Management's FTH Position: Q2 2025 in Review

Cresset Asset Management sold out of Faeth Therapeutics (FTH) in Q2 2025, closing a stake of 984 shares — an estimated $7.75K sold.

Cresset Asset Management first reported a position in FTH in Q1 2024 and held it in 5 quarters. The position peaked at $20.7K in Q1 2024. 10 funds tracked by Wall St. Rank hold FTH as of Q2 2025.

  • Cresset Asset Management reported no remaining Faeth Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cresset Asset Management sold 984 Faeth Therapeutics shares in Q2 2025, an estimated $7.75K.
  • Cresset Asset Management first reported a position in Faeth Therapeutics in Q1 2024 and held it in 5 quarters.
  • Cresset Asset Management's Faeth Therapeutics position peaked at $20.7K in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2025.

Based on Cresset Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.